Combination immunetherapy with CAR‐T ceils and checkpoint blockade hematolagical malignancy, combination PD‐1 blockade and CD19 CAR‐T cell therapy in B‐ALL patients improved outcomes and improved CART cell persistence. Here, CD19 is linked to acute lymphoblastic leukemia.